Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-targeted cell fusion.

Takafumi Nakamura1, Kah-Whye Peng, Sompong Vongpunsawad

  • 1Molecular Medicine Program, Mayo Foundation, 200 First St. SW, Rochester, Minnesota 55905, USA.

Nature Biotechnology
|March 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

Cancer research communications·2026
Same author

Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition.

Molecular therapy. Oncology·2026
Same author

Hepatic lipid quantity and quality in type 2 diabetes mellitus.

Frontiers in pharmacology·2026
Same author

Efficacy of intranasal adenovirus vector vaccine is attenuated by type I IFN-induced NK cell activation.

Molecular therapy. Advances·2026
Same author

Effects of cellular receptors on the vaccine efficacies of adenovirus vector-based vaccines following intramuscular and intranasal administration.

Scientific reports·2026
Same author

Liver-Specific Suppression of PLA2G6/iPLA<sub>2</sub>β Improves Glucose and Lipid Metabolism in High-Fat Diet-Fed Mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

Scientists engineered measles virus proteins to target specific cells for fusion. This antibody-targeted cell fusion technology shows potential for cancer therapy by selectively destroying tumor cells expressing specific receptors like EGFR.

Area of Science:

  • Biotechnology
  • Virology
  • Molecular Biology

Background:

  • Membrane fusion is crucial in biological processes and has biotechnological applications.
  • Viral glycoproteins mediate membrane fusion, offering a basis for engineered fusion systems.

Purpose of the Study:

  • To engineer antibody-targeted measles virus glycoproteins for specific cell fusion.
  • To evaluate the efficacy of engineered fusion proteins in targeting and eliminating cancer cells.

Main Methods:

  • Modified measles hemagglutinin (H) protein with single-chain antibodies to retarget fusion specificity.
  • Ablation of native receptor-binding ability of the H protein.
  • Coexpression of modified H protein and measles fusion (F) protein using adenoviral vectors.
  • Assessment of cell fusion and cytotoxicity in vitro and in vivo models.

Related Experiment Videos

Main Results:

  • Retargeted H proteins successfully mediated antibody-specific cell fusion with target cells.
  • Adenoviral vectors expressing EGFR-targeted H proteins demonstrated potent cytotoxicity against EGFR-positive tumor cell lines.
  • EGFR-targeted fusion vectors showed superior antitumor efficacy in xenograft models compared to untargeted or CD38-targeted vectors.

Conclusions:

  • Engineered viral glycoproteins enable precise antibody-targeted membrane fusion.
  • This approach offers a potent strategy for targeted cancer therapy, particularly against EGFR-expressing tumors.
  • The developed technology holds promise for advancing cell-based therapies and biotechnological applications.